These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 791325

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Drug-free research in schizophrenia: an overview of the controversy.
    Appelbaum PS.
    IRB; 1996; 18(1):1-5. PubMed ID: 11660192
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Muscimol: GABA agonist therapy in schizophrenia.
    Tamminga CA, Crayton JW, Chase TN.
    Am J Psychiatry; 1978 Jun; 135(6):746-7. PubMed ID: 350058
    [No Abstract] [Full Text] [Related]

  • 46. Evaluation of human subject protections in schizophrenia research conducted by the University of ... (Part I).
    Maloney DM.
    Hum Res Rep; 1999 Nov; 14(11):5-6. PubMed ID: 12194197
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Designing drug efficacy trials in the treatment of cocaine abuse.
    Satel SL, Kosten TR.
    J Nerv Ment Dis; 1991 Feb; 179(2):89-96. PubMed ID: 1990076
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Correct titration of non-drugs and some other methodological issues.
    Beneke M, Rasmus W, Rød IS, Fritze J.
    Neuropsychobiology; 1994 Feb; 30(1):37-41. PubMed ID: 7969857
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Improvement of phase III psychotropic drug trials by intensive phase II work.
    Klein DF.
    Neuropsychopharmacology; 1991 Jun; 4(4):251-8; discussion 259-71. PubMed ID: 1867735
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Guidelines for the use of placebo controls in clinical trials of psychopharmacologic agents. Loma Linda University Institutional Review Board.
    Orr RD.
    Psychiatr Serv; 1996 Nov; 47(11):1262-4. PubMed ID: 8916249
    [Abstract] [Full Text] [Related]

  • 60. Clinical development of atypical antipsychotics: research design and evaluation. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998 Nov; 59 Suppl 12():10-6. PubMed ID: 9766614
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.